Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents

What Was Tested

Researchers studied BNP (Nesiritide) in this randomized controlled trial publication.

The primary aim of the analysis was to assess the effect of 24 weeks of treatment with canagliflozin, relative to glimepiride, on N-terminal pro-brain natriuretic peptide (NT-proBNP) concentration in patients with T2D and clinically stable chronic HF.

Why It Was Studied

Recent guidelines recommend considering the use of SGLT2 inhibitors in patients with type 2 diabetes (T2D) and HF, irrespective of their glycemic control status and background use of other glucose-lowering agents including metformin.

However, only a small number of studies have investigated whether the effects of SGLT2 inhibitor in these patients differ by the concomitant use of other glucose-lowering agents.

Who Took Part

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

In the present analysis, the effect of canagliflozin on NT-proBNP concentration was assessed in the patients according to their baseline use of other glucose-lowering agents.

How the Study Was Run

The researchers set it up as a randomized, open-label and multicenter study.

Random assignment meant chance, not the researchers, decided who got BNP (Nesiritide) and who got the comparison, which limits bias.

Being open-label, the BNP (Nesiritide) study did not mask who received what.

More than one site took part, so the participants came from several places.

This was a post-hoc analysis of the CANDLE trial (UMIN000017669), an investigator-initiated, multicenter, open-label, randomized, controlled trial.

What Was Measured

PubMed files the paper under topics including Biomarkers, Blood Glucose, Canagliflozin, Chronic Disease, Diabetes Mellitus, Type 2, Glycemic Control and Heart Failure.

Author keywords: Chronic heart failure, Dipeptidyl peptidase-4 inhibitor, Metformin, Sodium–glucose cotransporter 2 inhibitor and Type 2 diabetes.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of BNP (Nesiritide).

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2021 (Cardiovascular diabetology), a journal based in England.

More context: the BNP (Nesiritide) compound page, all human trials.